Outcome of Board Meeting

Kilitch Drugs (India) Ltd. 13" August, 2026 To, To, The Manager - Corporate Relationship The Manager - Corporate Compliance Dept. National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot No.C-1, P. J. Towers, Dalal Street G Block, BKC, Bandra (E), Fort, Mumbai - 400 001 Mumbai 400 051 Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH Sub: Outcome of the Board Meeting Dear Sir, Pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, 13" August, 2026 have considered and approved the following; 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30" June, 2026. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith. The Board Meeting commenced at 16:30 hours and concluded at 20.40 hours. Request you to kindly take note of the same and acknowledge the receipt. Thanking you, Yours Faithfully, For Kilitch Drugs (India) Limited Mukund Mehta Managing Director DIN: 00147876 oxo. 139408051::22000038 WHO CEr RTIFIED Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. ¢ Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. e CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 « E-mail : info@kilitch.co m » Website : www.kilitch.com KILITCH DRUGS ( INDIA) LIMITED STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2626 Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com CIN:L24239MH1992PLC066718 (Rs. In Lakhs except Earnings per Share data) Three Months Ended Year Ended 30-06-2026 | 31-03-2026 | 30-06-2025 gf 1-03-2026 Unaudited Audited Unaudited Audited i {income Net Sales/ Income from operations 4,091.20 7,196.88 3,412.20 18,857.43 Other Income 354.76 113.63 349.52 1,384.85 Total lncome 4,445.96 7,310.51 3,761.72 20,242.28 ee Expenses Cost of Materials Consumed 2,024.54 2,853.23 1,826.71 8,780.36 Changes in Inventories of Finished Goods, Work-in- Progress and Stock-in-Trade (19.81) 146.91 (76.09) 106.73 Employee Benefit Expenses 352.50 361,37 239.50 1,233.50 Finance Cost 48.63 57.79 58.66 244.31 Depreciation and Amortisation Expenses 75.86 70,14 49.87 228.80 Export Product Registration/Commission SIOT? 522.98 590,50 2,139.01 Other Expenses 749.66 1,365.41 514.40 3,354.20 Total Expenses 3,751.16 5,377.83 3,163.55 16,086.91 3 Profit/ (Loss) before Exceptional items (1-2) 694,80 1,932.68 598.17 4,155.37 4 Exceptional Items 2 - - 5 Profit / (Loss) from ordinary activities before tax (3+4) 694.80 1,932.68 598.17 4,155.37 6 Less: Tax Expenses:- Current Tax 161.17 617.90 129.86 1,085.69 Deferred Tax 28.38 (85,12) (11.10) (170.28) Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6) 505.24 1,399.90 479,41 3,239.96 8 Other Comprehensive Income (after tax) 500.21 (221.17) 293.49 (106.50) 9 Total Comprehensive Income (after taxes) (7+8) 1,005.46 1,078.73 772.90 3,133.46 10 Paid-Up equity share capital (Face Value Rs 10 per share) 3,496.16 3,496.16 1,608.23 3,496.16 11 Other Equity 29,804.51 12 | Earning per share (not annualised) {a) Basie 1.45 4.08 1.49 9.57 (b) Diluted 1.45 4.08 1.49 9.57 Notes: 1. The above Unaudited Standalone Financial Results of the Company for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2026, 2. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly! by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108. 3. The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 3 gt March, 2026 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors. 4. The figures for the corresponding previous periods have been reclassified/regrouped, wherever necessary, to make them comparable wit h the g rel t periods, Place : Mumbai Managing Directo Dated: 13th Aug, 2026 DIN:- 01902831 C. Sharat & Associates CSA Chartered Accoutants Knowledge to Wisdom Independent Auditor’s Review Report on the Quarterly Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) g To, ‘ The Board of Directors of Kilitch Drugs (India) Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Kilitch Drugs (India) Limited (the ‘Company’) for the quarter ended 30" June, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the “Listing Regulations”). 2. The Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in india. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Sta ndar ds (‘Ind AS’) specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, inciuding the manner in which it is to be disclosed, or that it contains any material misstatement. For, C. Sharat & Associat es Chartered Accountants FRN: 128593W fl) Chintan Shah [yale Al ow ilo. 127554 Chintan ¥haratchandra Shah Partner Mem.No: 127551 UDIN No: 26127551CQMGKK7150 Place: Mumbai Date:13/08/2026 KILITCH DRUGS ( INDIA) LIMITED CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026 Regd. Office:- C-301/2, MIDC, TTC In [Showing first 8,000 characters — download PDF for full document]